Corcept Therapeutics reported third quarter 2026 revenue of $340.5 million, up 64 percent from the same period in 2025, and net income of $126.8 million, compared with $19.7 million a year earlier. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, and its Lifyorli ovarian cancer product contributed $91.4 million of the quarter's revenue.
Q3 2026 revenue of $340.5 million vs. $207.6 million in Q3 2025; Korlym and authorized generic revenue was $249.1 million and Lifyorli revenue was $91.4 million
Q3 2026 net income of $126.8 million, or $1.01 per diluted share, vs. $19.7 million, or $0.16 per diluted share, in Q3 2025
2026 revenue guidance of $1.1 billion to $1.2 billion reiterated; cash and investments rose to $662.3 million at September 30, 2026
Relacorilant for Cushing's syndrome has a PDUFA date of December 17, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Corcept Therapeutics's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$761.41M
+12.8%
$0.82
-33.3%
13.1%
FY2024
$675.04M
+39.9%
$1.23
+30.9%
20.9%
FY2023
$482.38M
+20.0%
$0.94
+8.0%
22.0%
FY2022
$401.86M
+9.8%
$0.87
-2.2%
25.2%
FY2021
$365.98M
+3.4%
$0.89
+4.7%
30.7%
Frequently asked questions
When is Corcept Therapeutics's next earnings date?
Corcept Therapeutics has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Corcept Therapeutics earn last quarter?
For the quarter ended Sep 2026, Corcept Therapeutics reported diluted EPS of $1.01 (+531.2% year over year) on revenue of $340.47M (+64.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.